AP2287A - Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication. - Google Patents

Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.

Info

Publication number
AP2287A
AP2287A AP2006003579A AP2006003579A AP2287A AP 2287 A AP2287 A AP 2287A AP 2006003579 A AP2006003579 A AP 2006003579A AP 2006003579 A AP2006003579 A AP 2006003579A AP 2287 A AP2287 A AP 2287A
Authority
AP
ARIPO
Prior art keywords
acylsulfonamides
inhibitors
carboxylic acids
hcv replication
macrocyclic carboxylic
Prior art date
Application number
AP2006003579A
Other languages
English (en)
Other versions
AP2006003579A0 (en
Inventor
Steven Andrews
Lawrence M Blatt
Kevin Ronald Condroski
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of AP2006003579A0 publication Critical patent/AP2006003579A0/xx
Application granted granted Critical
Publication of AP2287A publication Critical patent/AP2287A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AP2006003579A 2003-10-14 2004-10-13 Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication. AP2287A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51154103P 2003-10-14 2003-10-14
US61246004P 2004-09-22 2004-09-22
PCT/US2004/033970 WO2005037214A2 (en) 2003-10-14 2004-10-13 Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication

Publications (2)

Publication Number Publication Date
AP2006003579A0 AP2006003579A0 (en) 2006-04-30
AP2287A true AP2287A (en) 2011-10-31

Family

ID=34467992

Family Applications (2)

Application Number Title Priority Date Filing Date
AP2006003579A AP2287A (en) 2003-10-14 2004-10-13 Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
AP2011005830A AP2011005830A0 (en) 2003-10-14 2006-04-11 Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AP2011005830A AP2011005830A0 (en) 2003-10-14 2006-04-11 Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.

Country Status (29)

Country Link
EP (2) EP1680137B1 (is)
JP (3) JP4584260B2 (is)
KR (1) KR100853579B1 (is)
CN (2) CN102020697B (is)
AP (2) AP2287A (is)
AR (2) AR046422A1 (is)
AU (1) AU2004281780B2 (is)
BR (1) BRPI0415373A (is)
CA (1) CA2540858C (is)
CY (1) CY1113809T1 (is)
DK (1) DK1680137T3 (is)
EA (1) EA011857B8 (is)
EC (2) ECSP066570A (is)
ES (1) ES2398912T3 (is)
GE (1) GEP20084560B (is)
HR (1) HRP20130098T1 (is)
IL (3) IL174704A (is)
IS (1) IS2876B (is)
MA (1) MA28152A1 (is)
MX (1) MXPA06003963A (is)
MY (1) MY144593A (is)
NO (1) NO343231B1 (is)
NZ (1) NZ546347A (is)
OA (1) OA13315A (is)
PL (1) PL1680137T3 (is)
PT (1) PT1680137E (is)
RS (3) RS20110578A3 (is)
TW (2) TW201245229A (is)
WO (1) WO2005037214A2 (is)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
TW201245229A (en) * 2003-10-14 2012-11-16 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
BRPI0509467A (pt) * 2004-03-30 2007-09-11 Intermune Inc compostos macrocìclicos como inibidores de replicação viral
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5667745B2 (ja) * 2005-03-08 2015-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状化合物を製造する方法
RU2458919C2 (ru) 2005-04-13 2012-08-20 Астекс Терапьютикс Лимитед ПРОИЗВОДНЫЕ ГИДРОКСИБЕНЗАМИДА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Hsp90
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2007002051A1 (en) * 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
US7601686B2 (en) * 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA019888B1 (ru) 2005-07-25 2014-07-30 Интермьюн, Инк. Промежуточное соединение для получения макроциклических ингибиторов репликации вируса гепатита с и способ его синтеза
TWI383980B (zh) 2005-07-29 2013-02-01 Tibotec Pharm Ltd Ｃ型肝炎病毒之大環抑制劑
MY144607A (en) * 2005-07-29 2011-10-14 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
JP5230415B2 (ja) 2005-07-29 2013-07-10 テイボテク・フアーマシユーチカルズ Ｃ型肝炎ウイルスの大員環状阻害剤
WO2007019674A1 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
ATE493409T1 (de) * 2005-10-11 2011-01-15 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2386539B1 (en) 2005-12-23 2016-07-20 Zealand Pharma A/S 4-Aminoproline derivatives useful as lysine mimetics
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
NZ574605A (en) 2006-07-13 2011-11-25 Achillion Pharmaceuticals Inc 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
MX2009000882A (es) 2006-08-17 2009-02-04 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
MX2009002781A (es) * 2006-09-15 2009-03-30 Reviva Pharmaceuticals Inc Sintesis, metodos de uso y composiciones de cicloalquilmetilaminas .
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK2468724T3 (en) 2006-12-21 2016-02-22 Zealand Pharma As Synthesis of pyrrolidine compounds
CN101668538A (zh) * 2007-01-08 2010-03-10 芬诺密克斯公司 大环类丙型肝炎蛋白酶抑制剂
CN101589040A (zh) * 2007-02-01 2009-11-25 泰博特克药品有限公司 Hcv巨环抑制剂的多晶形
US8435984B2 (en) 2007-02-26 2013-05-07 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of HCV replication
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
DE602008003922D1 (de) * 2007-04-24 2011-01-20 Hoffmann La Roche Verfahren für hcv-proteasehemmerzwischenprodukt
US20090155209A1 (en) * 2007-05-03 2009-06-18 Blatt Lawrence M Novel macrocyclic inhibitors of hepatitis c virus replication
KR20100027134A (ko) 2007-05-10 2010-03-10 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 펩티드 억제제
CA2691442C (en) * 2007-06-29 2014-01-21 Gilead Sciences, Inc. Antiviral compounds
SG182979A1 (en) 2007-06-29 2012-08-30 Gilead Sciences Inc Antiviral compounds
SE531698C2 (sv) 2007-07-12 2009-07-07 Respiratorius Ab Nya bronkdilaterande a,b-omättade amider
US8242140B2 (en) 2007-08-03 2012-08-14 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
WO2009076173A2 (en) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Fluorinated tripeptide hcv serine protease inhibitors
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
KR101683559B1 (ko) 2007-12-21 2016-12-08 셀진 아빌로믹스 리서치, 인코포레이티드 Ｈｃｖ 프로테아제 억제제 및 이의 용도
CN101951769B (zh) 2007-12-21 2014-12-31 阿维拉制药公司 Hcv蛋白酶抑制剂和其用途
CN101903391B (zh) * 2007-12-21 2013-04-03 弗·哈夫曼-拉罗切有限公司 大环化合物的制备方法
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
BRPI0908021A2 (pt) 2008-02-04 2015-07-21 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
KR101216900B1 (ko) 2008-04-11 2012-12-28 에프. 호프만-라 로슈 아게 복분해 반응을 위한 촉매로서의 신규 루테늄 착물
BRPI0911260A2 (pt) * 2008-04-15 2015-09-29 Intermune Inc composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2722867A1 (en) 2008-05-09 2009-11-12 Boehringer Ingelheim International Gmbh A method for preparing macrocycles
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0916609A2 (pt) * 2008-08-07 2015-08-04 Hoffmann La Roche Processo para a preparação de um macrociclo
WO2010025510A1 (en) * 2008-09-03 2010-03-11 Xenome Ltd Libraries of peptide conjugates and methods for making them
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102245599B (zh) 2008-12-10 2014-05-14 艾其林医药公司 作为病毒复制抑制剂的新的4-氨基-4-氧代丁酰基肽
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010075554A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
AU2010203656A1 (en) 2009-01-07 2011-07-21 Scynexis, Inc. Cyclosporine derivative for use in the treatment of HCV and HIV infection
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
EP2403860B1 (en) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
JP2012523419A (ja) 2009-04-08 2012-10-04 イデニク プハルマセウティカルス，インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
CN102458444A (zh) 2009-05-13 2012-05-16 英安塔制药有限公司 用作丙型肝炎病毒抑制剂的大环化合物
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9096518B2 (en) 2009-06-22 2015-08-04 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
WO2011038293A1 (en) * 2009-09-28 2011-03-31 Intermune, Inc. Cyclic peptide inhibitors of hepatitis c virus replication
WO2011038283A1 (en) * 2009-09-28 2011-03-31 Hoffmann-La Roche Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US20120202787A1 (en) 2009-10-20 2012-08-09 Pfizer Inc. Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
CA2784748A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2528436A4 (en) 2010-01-25 2013-07-10 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
JP5833022B2 (ja) 2010-01-27 2015-12-16 エービー・ファーマ・リミテッド Ｃ型肝炎ウィルス阻害剤としてのポリ複素環式化合物
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
RS54368B1 (sr) 2010-03-31 2016-04-28 Gilead Pharmasset Llc Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat
KR102163902B1 (ko) 2010-09-21 2020-10-12 이난타 파마슈티칼스, 인코포레이티드 매크로사이클릭 프롤린 유도된 ｈｃｖ 세린 프로테아제 억제제
TW201300106A (zh) 2010-11-09 2013-01-01 Hoffmann La Roche 治療ｈｃｖ感染之醫藥組合物
EP2455068A1 (en) 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
CN103313968A (zh) 2010-11-15 2013-09-18 Abbvie公司 Nampt和rock抑制剂
KR101770873B1 (ko) 2010-11-18 2017-08-23 메탈리시스 리미티드 전기분해 장치
EP3042910B1 (en) 2010-11-30 2019-01-09 Gilead Pharmasset LLC 2'-spiro-nucleosides for use in the therapy of hepatitis c
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
CN103443092B (zh) 2011-02-03 2015-11-25 鲁平有限公司 用作α7胆碱受体调节剂的吡咯衍生物
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2012269643A1 (en) 2011-06-16 2014-02-06 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
WO2013059405A1 (en) 2011-10-18 2013-04-25 Coherus Biosciences, Inc. Etanercept formulations stabilized with amino acids
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
BR112014006314A2 (pt) 2011-10-21 2017-04-11 Abbvie Inc métodos para tratamento do vírus da hepatite c (hcv) compreendendo pelo menos dois agentes antivirais de atuação direta, ribavirina, sem interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
KR20140110014A (ko) 2011-12-30 2014-09-16 레비바 파마슈티칼스, 아이엔씨. 페닐시클로알킬메틸아민 유도체의 조성물, 합성, 및 사용 방법
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
JP6271536B2 (ja) 2012-07-09 2018-01-31 コヒラス・バイオサイエンシズ・インコーポレイテッド 肉眼不可視粒子の著しい低減を示すエタネルセプト製剤
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CN104902914B (zh) 2012-09-11 2019-01-01 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
AU2014236502A1 (en) 2013-03-14 2015-10-01 Achillion Pharmaceuticals, Inc. Processes for producing Sovaprevir
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
MX2015013020A (es) 2013-03-15 2016-06-10 Achillion Pharmaceuticals Inc Polimorfos de sovaprevir y metodos de fabricacion de los mismos.
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
EP3114122A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid forms of a flaviviridae virus inhibitor compound and salts thereof
CN105175491B (zh) * 2015-07-13 2019-01-11 山东大学 一种含有羟脯氨酸骨架的多肽类ns3丝氨酸蛋白酶抑制剂及其制备方法和应用
CN109689063B (zh) 2016-04-28 2026-02-27 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
CN110709096B (zh) 2017-05-05 2023-10-31 泽兰德制药公司 细胞间隙连接通讯调节剂及其在糖尿病性眼病治疗中的应用
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053349A2 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Inhibitors of hepatitis c virus
WO2003066103A1 (en) * 2002-02-07 2003-08-14 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis c viral protease inhibitors
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547119A (en) 1967-12-08 1970-12-15 Baxter Laboratories Inc Catheter assembly
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US4311137A (en) 1980-04-30 1982-01-19 Sherwood Medical Industries Inc. Infusion device
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4531937A (en) 1983-01-24 1985-07-30 Pacesetter Systems, Inc. Introducer catheter apparatus and method of use
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
MX9203641A (es) 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
US4755173A (en) 1986-02-25 1988-07-05 Pacesetter Infusion, Ltd. Soft cannula subcutaneous injection set
US5082659A (en) 1986-10-06 1992-01-21 Board Of Regents, The University Of Texas System Methods and compositions employing interferon-gamma
US5190751A (en) 1987-01-20 1993-03-02 Schering Corporation Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
ES2039276T3 (es) 1987-01-20 1993-09-16 Schering Corporation Uso de una combinacion de interferon gamma e interferon alfa para la preparacion de un medicamento para el tratamiento de ciertas leucemias.
EP0294160A1 (en) 1987-06-02 1988-12-07 Schering Corporation Treatment of chronic type b hepatitis with a combination of recombinant human alpha and gamma interferons
CN1074422C (zh) * 1987-11-18 2001-11-07 希龙股份有限公司 制备含有hcv表位的分离多肽的方法
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8904009D0 (en) 1989-02-22 1989-04-05 Celltech Ltd Vector
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5716632A (en) 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5518729A (en) 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
ATE241704T1 (de) * 1991-08-27 2003-06-15 Hoffmann La Roche Primers und sondern zum nachweis von hepatitis c
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5545143A (en) 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
US5500208A (en) 1994-06-07 1996-03-19 The Procter & Gamble Company Oral compositions comprising a novel tripeptide
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5559101A (en) 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
IL116730A0 (en) 1995-01-13 1996-05-14 Amgen Inc Chemically modified interferon
US6090822A (en) 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
GB9517022D0 (en) 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US5908121A (en) 1996-03-11 1999-06-01 Dardashti; Shahriar Adjustable display assembly
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
AU2933797A (en) 1996-05-10 1997-12-05 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
PL332638A1 (en) 1996-10-09 1999-09-27 Boehringer Mannheim Pharm Corp Method of inhibiting stress-activated proteinous kinases
WO1998016184A2 (en) 1996-10-16 1998-04-23 Icn Pharmaceuticals, Inc. Purine l-nucleosides, analogs and uses thereof
PL194025B1 (pl) 1996-10-18 2007-04-30 Vertex Pharma Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
AU7127298A (en) 1997-04-14 1998-11-11 Emory University Serine protease inhibitors
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
PT1003775E (pt) 1997-08-11 2005-07-29 Boehringer Ingelheim Ca Ltd Peptidos inibidores da hepatite c
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6046305A (en) 1997-12-12 2000-04-04 Macromed, Inc. Heterofunctionalized star-shaped poly(ethylene gycols) for protein modification
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6423695B1 (en) 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
DK1066247T3 (da) 1998-03-31 2007-04-02 Vertex Pharma Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease
KR20010025087A (ko) 1998-05-22 2001-03-26 스튜어트 알. 수터 신규한 2-알킬 치환된 이미다졸 화합물
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6492423B1 (en) 1998-07-27 2002-12-10 Istituto Di Ricerche Di Biologia Molecolare Pangeletti Spa Diketoacid-derivatives as inhibitors of polymerases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
CN1324250A (zh) 1998-09-04 2001-11-28 维洛药品公司 治疗或预防病毒感染及其所致疾病的方法
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6288089B1 (en) 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
NZ515861A (en) 1999-05-04 2004-08-27 Boehringer Ingelheim Ca Ltd Surrogate cell-based system and method for assaying the activity of hepatitis C virus NS3 protease
KR20020065517A (ko) 1999-11-12 2002-08-13 맥시겐 홀딩스 리미티드 인터페론 감마 접합체
HUP0202263A3 (en) 1999-12-27 2003-02-28 Japan Tobacco Inc Benzimidazole, indole and imidazo-pyridine derivatives and pharmaceutical compositions containing them
US6943161B2 (en) 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
RU2270194C2 (ru) 2000-05-22 2006-02-20 Лео Фарма А/С Бензофеноны как ингибиторы il-1бета и tnf-альфа, фармацевтическая композиция и способ лечения
PY0111577A (es) 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
IL156641A0 (en) 2001-01-22 2004-01-04 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2002064456A1 (en) * 2001-02-12 2002-08-22 Flextank Pty Ltd Liquid food and wine storage bladder within a container
AU2002252183A1 (en) 2001-03-06 2002-09-19 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
WO2002083622A2 (en) 2001-04-10 2002-10-24 Leo Pharma A/S Novel aminophenyl ketone derivatives
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
AU2002344854B2 (en) 2001-06-11 2008-11-06 Vertex Pharmaceuticals (Canada) Incorporated Thiophene derivatives as antiviral agents for flavivirus infection
JP2005500287A (ja) 2001-06-11 2005-01-06 シャイアー バイオケム インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の処置または予防のための化合物および方法
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2369711A1 (en) * 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
TW201245229A (en) * 2003-10-14 2012-11-16 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
WO2003053349A2 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Inhibitors of hepatitis c virus
WO2003066103A1 (en) * 2002-02-07 2003-08-14 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis c viral protease inhibitors

Also Published As

Publication number Publication date
DK1680137T3 (da) 2013-02-18
HK1182710A1 (zh) 2013-12-06
IS8395A (is) 2006-03-31
RS54573B1 (sr) 2016-06-30
AR080189A2 (es) 2012-03-21
RS20060259A (sr) 2008-08-07
ECSP066570A (es) 2006-10-17
CN103145715A (zh) 2013-06-12
WO2005037214A2 (en) 2005-04-28
JP2013006870A (ja) 2013-01-10
EP1680137A2 (en) 2006-07-19
JP5143870B2 (ja) 2013-02-13
JP2010248236A (ja) 2010-11-04
AP2006003579A0 (en) 2006-04-30
JP4584260B2 (ja) 2010-11-17
IL215933A0 (en) 2011-12-29
RS20110578A2 (sr) 2012-08-31
GEP20084560B (en) 2008-12-10
MY144593A (en) 2011-10-14
CN102020697B (zh) 2014-10-29
HRP20130098T1 (hr) 2013-02-28
AP2011005830A0 (en) 2011-08-31
WO2005037214A3 (en) 2005-11-03
CN102020697A (zh) 2011-04-20
PT1680137E (pt) 2013-02-21
JP2007533642A (ja) 2007-11-22
IL215934A0 (en) 2011-12-29
IL174704A (en) 2012-12-31
IS2876B (is) 2014-04-15
EA011857B8 (ru) 2012-08-30
TW201245229A (en) 2012-11-16
MXPA06003963A (es) 2006-08-25
KR100853579B1 (ko) 2008-08-21
ECSP12011944A (es) 2012-07-31
EP1680137A4 (en) 2010-04-28
NO343231B1 (no) 2018-12-10
TW200526685A (en) 2005-08-16
CN103145715B (zh) 2016-08-03
AU2004281780B2 (en) 2009-03-19
IL174704A0 (en) 2006-08-20
ES2398912T3 (es) 2013-03-22
BRPI0415373A (pt) 2006-12-12
CA2540858C (en) 2009-12-08
AR046422A1 (es) 2005-12-07
CY1113809T1 (el) 2016-07-27
HK1100164A1 (en) 2007-09-07
PL1680137T3 (pl) 2013-04-30
NZ546347A (en) 2009-11-27
RS20110578A3 (en) 2016-02-29
EA011857B1 (ru) 2009-06-30
NO20062089L (no) 2006-05-09
TWI375679B (en) 2012-11-01
EP2407470A3 (en) 2015-06-10
AU2004281780A1 (en) 2005-04-28
OA13315A (en) 2007-04-13
CA2540858A1 (en) 2005-04-28
MA28152A1 (fr) 2006-09-01
EP1680137B1 (en) 2012-11-21
KR20070033315A (ko) 2007-03-26
EA200600732A1 (ru) 2006-08-25
EP2407470A2 (en) 2012-01-18

Similar Documents

Publication Publication Date Title
AP2287A (en) Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
IL182712A0 (en) (biphenyl) carboxylic acids and derivatives thereof
AU2003261434A8 (en) Iminothiazolidinones as inhibitors of hcv replication
IL183808A0 (en) Hydroxybiphenyl carboxylic acids and derivatives, method for producing the same and their use
IL193071A0 (en) Cyclopropyl carboxylic acid esters and derivatives
TWI306412B (en) Homogeneous process for the hydrogenation of carboxylic acids and/or derivatives thereof
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
IL180738A0 (en) Inhibitors of hcv replication
MXPA03009565A (es) Derivado de acido carboxilico y una sal del mismo.
AU2003221786A1 (en) Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
IL183288A0 (en) Biaryloxymethylarene carboxylic acids
IL172471A0 (en) Gsk-3 inhibitors and uses thereof
ZA200701583B (en) Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
ZA200410054B (en) Propionic acid derivatives and their use as hPPARsactivators.
AU2003301883A1 (en) Modified luciferase nucleic acids and methods of use
IL176772A0 (en) Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors
PL373315A1 (en) Preparations containing diformates and short-chain carboxylic acids
ZA200700854B (en) Inhibitors of HCV replication
AU2003258564A1 (en) Gas odorisation using carboxylic acids and alkynes
SI1680137T1 (sl) Makrocikliäśna karboksilna kislina in acilsulfonamidna spojina kot inhibitor replikacije hcv
AU2002368547A1 (en) Methods of sterilizing with dipercarboxylic acids
AU2003215146A8 (en) Snares and methods of controlling cytokinesis
ZA200703258B (en) (Biphenyl) carboxylic acids and derivatives thereof
PL361610A1 (en) New unsaturated cis-dialkyl gamma-lactone and method of its receiving
PL361609A1 (en) New unsaturated gamma-lactone and method of its receiving